Showing results (1-10 of 7,033) with videos related to
Sort By:
Pageof 704
Journal of Clinical Medicine|January 10, 2026
A Vanished Association Between Proton Pump Inhibitors and Clostridioides Difficile Infection After Minimizing BiasBin Wu, Zhiyao He, Ting XuScientific Reports|February 12, 2021
Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting systemBin Wu, Dan Li, Ting Xu, et al.Frontiers in Pharmacology|April 11, 2022
Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERSBin Wu, Min Luo, Fengbo Wu, et al.Frontiers in Public Health|March 21, 2022
Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 StudyMei Zhan, Ting Xu, Hanrui Zheng, et al.Journal of Clinical Medicine|May 27, 2023
Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting SystemChunyan Wei, Wanhong Yin, Zhiyao He, et al.Frontiers in Pharmacology|November 28, 2024
Predicting adverse drug event using machine learning based on electronic health records: a systematic review and meta-analysisQiaozhi Hu, Yuxian Chen, Dan Zou, et al.Signal Transduction and Targeted Therapy|June 8, 2021
Recent progress in targeted delivery vectors based on biomimetic nanoparticlesLi Chen, Weiqi Hong, Wenyan Ren, et al.The Journal of International Medical Research|December 13, 2024
Machine learning to predict adverse drug events based on electronic health records: a systematic review and meta-analysisQiaozhi Hu, Jiafeng Li, Xiaoqi Li, et al.Computational and Structural Biotechnology Journal|July 16, 2019
Applications of Genome Editing Technology in Animal Disease Modeling and Gene TherapyQian Li, Zhou Qin, Qingnan Wang, et al.Cancer Management and Research|December 28, 2020
Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO TrialMei Zhan, Hanrui Zheng, Yu Yang, et al.Pageof 704